Borderline ovarian tumors (BLOTs), also called semi-malignant ovarian tumors, despite a clear classification, represent one of the most controversial topics in oncogynecology. Although it is not a rare diagnosis, there are no prospective randomized studies showing clear recommendations regarding the management of this disease. The disease incidence reaches its peak when women attain their reproductive age, thus, a fertility sparing approach is often the goal of the treatment. Surgery remains the main therapeutic strategy. A clear definition for low-or high-risk patients requiring more or less aggressive treatment is lacking. Nowadays, the main factors deciding the range of therapeutic approach depends upon the histopathological features; particularly the presence of invasive implants and microinvasion, as well as the staging of the disease. Recent genetic assessment has brought new knowledge, but the extrapolation to clinical practice is still missing.